Pharmacodynamic resistance to warfarin associated with a Val66Met substitution in vitamin K epoxide reductase complex subunit I

被引:102
作者
Harrington, DJ
Underwood, S
Morse, C
Shearer, MJ
Tuddenham, EGD
Mumford, AD [1 ]
机构
[1] Bristol Royal Infirm & Gen Hosp, Dept Haematol, Bristol BS2 8HW, Avon, England
[2] St Thomas Hosp, Ctr Haemostasis & Thrombosis, London, England
[3] Univ London Imperial Coll Sci Technol & Med, MRC Clin Sci Ctr, London, England
关键词
warfarin resistance; vitamin K; vitamin K epoxide reductase; pharmacogenetics; coagulation factor;
D O I
10.1160/TH04-08-0540
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The gene encoding vitamin K epoxide reductase complex subunit I (VKORCI), a component of the enzyme that is the therapeutic target site for warfarin, has recently been identified. In order to investigate the relationship between VKORCI I and warfarin dose response, we studied the VKORCI gene (VKORCI) in patients with warfarin resistance. From a study group of 820 patients,we identified 4 individuals who required more than 25 mg of warfarin daily for therapeutic anti coagulation. Three of these had serum warfarin concentrations within the therapeutic range of 0.7-2.3 mg/l and showed wild-type VKORCI sequence. The fourth warfarin resistant individual had consistently high (greater than or equal to5.7 mg/l) serum warfarin concentrations, yet had no clinically discernible cause for warfarin resistance. VKORCI showed a heterozygous 196G-->A transition that predicted aVal66Met substitution in the VKORCI polypeptide. This transition was also identified in 2 asymptomatic family members who had never received warfarin. These individuals had normal vitamin-K dependent coagulation factor activities and undetectable serum PIVKA-II and vitamin K-I 2,3 epoxide suggesting that their basal vitamin K epoxide reductase activity was not adversely affected by the VKORCI Val66Met substitution. The association between a nucleotide transition in VKORCI and pharmacodynamic warfarin resistance supports the hypothesis that VKORCI is the site of action of warfarin and indicates that VKORCI sequence is an important determinant of the warfarin dose response.
引用
收藏
页码:23 / 26
页数:4
相关论文
共 22 条
  • [1] HEREDITARY WARFARIN RESISTANCE - INVESTIGATION OF A RARE PHENOMENON
    ALVING, BM
    STRICKLER, MP
    KNIGHT, RD
    BARR, CF
    BERENBERG, JL
    PECK, CC
    [J]. ARCHIVES OF INTERNAL MEDICINE, 1985, 145 (03) : 499 - 501
  • [2] PRODUCTION OF A NEW MONOCLONAL-ANTIBODY SPECIFIC TO HUMAN DES-GAMMA-CARBOXYPROTHROMBIN IN THE PRESENCE OF CALCIUM-IONS - APPLICATION TO THE DEVELOPMENT OF A SENSITIVE ELISA-TEST
    BELLE, M
    BREBANT, R
    GUINET, R
    LECLERCQ, M
    [J]. JOURNAL OF IMMUNOASSAY, 1995, 16 (02): : 213 - 229
  • [3] INVESTIGATION OF PATIENTS WITH ABNORMAL RESPONSE TO WARFARIN
    BENTLEY, DP
    BACKHOUSE, G
    HUTCHINGS, A
    HADDON, RL
    SPRAGG, B
    ROUTLEDGE, PA
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1986, 22 (01) : 37 - 41
  • [4] DANDREA G, 2004, BLOOD 0909
  • [5] Davidson KW, 1997, METHOD ENZYMOL, V282, P408
  • [6] HEREDITARY WARFARIN RESISTANCE
    DIAB, F
    FEFFER, S
    [J]. SOUTHERN MEDICAL JOURNAL, 1994, 87 (03) : 407 - 409
  • [7] Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin
    Gage, BF
    Eby, C
    Milligan, PE
    Banet, GA
    Duncan, JR
    McLeod, HL
    [J]. THROMBOSIS AND HAEMOSTASIS, 2004, 91 (01) : 87 - 94
  • [8] Vitamin K epoxide reductase: homology, active site and catalytic mechanism
    Goodstadt, L
    Ponting, CP
    [J]. TRENDS IN BIOCHEMICAL SCIENCES, 2004, 29 (06) : 289 - 292
  • [9] HIGH CLEARANCE OF (S)-WARFARIN IN A WARFARIN-RESISTANT SUBJECT
    HALLAK, HO
    WEDLUND, PJ
    MODI, MW
    PATEL, IH
    LEWIS, GL
    WOODRUFF, B
    TROWBRIDGE, AA
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1993, 35 (03) : 327 - 330
  • [10] American Heart Association/American College of Cardiology Foundation guide to warfarin therapy
    Hirsh, J
    Fuster, V
    Ansell, J
    Halperin, JL
    [J]. CIRCULATION, 2003, 107 (12) : 1692 - 1711